US Patent

US12364699 — Method of treating hair loss disorders

Method of Use · Assigned to Sun Pharmaceutical Industries Inc · Expires 2044-10-10 · 18y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating Alopecia Areata using Compound (I) or a pharmaceutically acceptable salt thereof.

USPTO Abstract

The disclosure relates to treatment of Alopecia Areata comprising the administration of Compound (I) or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

deuruxolitinib-phosphate (DEURUXOLITINIB PHOSPHATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3976`	—	deuruxolitinib-phosphate

Patent Metadata

Patent number: US12364699
Jurisdiction: US
Classification: Method of Use
Expires: 2044-10-10
Drug substance claim: No
Drug product claim: No
Assignee: Sun Pharmaceutical Industries Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.